Anticancer metallodrugs: where is the next cisplatin?

Area of Science:

• Medicinal Chemistry
• Oncology
• Nanotechnology

Background:

• DNA-targeting platinum drugs are mainstays in chemotherapy but face challenges like drug resistance and severe side effects.
• There is a critical need for novel anticancer agents with improved efficacy and reduced toxicity.

Purpose of the Study:

• To explore new strategies and formulations for anticancer metal complexes.
• To design metal-based drugs with nonclassical mechanisms of action.
• To develop agents capable of selective biomolecular targeting and inducing immunogenic anticancer activity.

Main Methods:

• Design and synthesis of novel metal-based anticancer complexes.
• In vitro and in vivo evaluation of efficacy and toxicity.
• Investigation of mechanisms of action, including DNA interaction and immunomodulation.

Main Results:

• Emerging metal complexes demonstrate nonclassical anticancer activity.
• Potential for selective targeting of cancer cells and induction of immune responses.
• Promising strategies to overcome platinum drug resistance and systemic toxicity.

Conclusions:

• Novel metal complexes offer a promising alternative to traditional platinum drugs.
• These developments aim to ameliorate systemic toxicity and expand the spectrum of treatable cancers.
• Future research will focus on optimizing formulations for clinical application.